Tumor necrosis factor-α at the intersection of mycobacterial immunity and pathogenesis: An important new address in medicine

Clinical Infectious Diseases

Volumn 46, Issue 11, 2008, Pages 1741-1742

  Iseman, Michael D ^a,b   Fischer, Aryeh ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; ISONIAZID; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; AUTOIMMUNITY; BACTERIAL IMMUNITY; DEMYELINATING DISEASE; DRUG EFFICACY; HEART FAILURE; HUMAN; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; MALIGNANT NEOPLASTIC DISEASE; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT INDICATION; TUBERCULOSIS;

HUMANS; MYCOBACTERIUM; PHARMACEUTICAL PREPARATIONS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43949115955     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587990     Document Type: Note

References (6)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72:3666-70.
2. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-TNF-α therapy. Arthritis Rheum 2003; 48:3013-22.
3. Winthrop KL, Yamashita S, Beekman SE, Polgreen PM. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008; 46:1738-40 (in this issue).
4. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2:602-10.
5. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006; 295:2275-85 (erratum: JAMA 2006; 295:2482).
6. Listing J, Strangefeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:3403-12.